DIPG-61. RESCUE REGIMENS AFTER BIOMEDE: POSSIBLE INFLUENCE ON OS ASSESSMENT

BIOMEDE is a multicentric randomized phase II trial to evaluate in DIPG the OS of patients treated with dasatinib, erlotinib or everolimus. The OS is the result of the first line treatment but it could also be affected by re-irradiation and the second line treatment received after progression, espec...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Carlo, Daniela Di, Pommier, Bertille, Teuff, Gwenael Le, Abbou, Samuel, Berlanga, Pablo, Geoerger, Birgit, Puget, Stephanie, Beccaria, Kevin, Blauwblomme, Thomas, Debily, Marie-Anne, Castel, David, Lechapt, Emmanuelle, Varlet, Pascale, Dangouloff-Ros, Volodia, Boddaert, Nathalie, Vassal, Gilles, Deley, Marie-Cécile Le, Grill, Jacques
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2020
Témata:
Diffuse Midline Glioma/DIPG
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7715765/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa222.106
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky